AU2016335912B2 - Antibodies with improved stability to intestinal digestion - Google Patents

Antibodies with improved stability to intestinal digestion Download PDF

Info

Publication number
AU2016335912B2
AU2016335912B2 AU2016335912A AU2016335912A AU2016335912B2 AU 2016335912 B2 AU2016335912 B2 AU 2016335912B2 AU 2016335912 A AU2016335912 A AU 2016335912A AU 2016335912 A AU2016335912 A AU 2016335912A AU 2016335912 B2 AU2016335912 B2 AU 2016335912B2
Authority
AU
Australia
Prior art keywords
antibody
bovine
antibodies
domain
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016335912A
Other languages
English (en)
Other versions
AU2016335912A1 (en
Inventor
Randall Edward Burton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circle33 LLC
Original Assignee
Circle33 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circle33 LLC filed Critical Circle33 LLC
Publication of AU2016335912A1 publication Critical patent/AU2016335912A1/en
Priority to AU2023216791A priority Critical patent/AU2023216791A1/en
Application granted granted Critical
Publication of AU2016335912B2 publication Critical patent/AU2016335912B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016335912A 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion Active AU2016335912B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023216791A AU2023216791A1 (en) 2015-10-05 2023-08-16 Antibodies with improved stability to intestinal digestion

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237270P 2015-10-05 2015-10-05
US62/237,270 2015-10-05
PCT/US2016/054304 WO2017062253A2 (en) 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023216791A Division AU2023216791A1 (en) 2015-10-05 2023-08-16 Antibodies with improved stability to intestinal digestion

Publications (2)

Publication Number Publication Date
AU2016335912A1 AU2016335912A1 (en) 2018-05-24
AU2016335912B2 true AU2016335912B2 (en) 2023-08-31

Family

ID=58488349

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016335912A Active AU2016335912B2 (en) 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion
AU2023216791A Pending AU2023216791A1 (en) 2015-10-05 2023-08-16 Antibodies with improved stability to intestinal digestion

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023216791A Pending AU2023216791A1 (en) 2015-10-05 2023-08-16 Antibodies with improved stability to intestinal digestion

Country Status (8)

Country Link
US (2) US11891440B2 (OSRAM)
EP (1) EP3359190A4 (OSRAM)
JP (2) JP7235287B2 (OSRAM)
AU (2) AU2016335912B2 (OSRAM)
BR (1) BR112018006953A2 (OSRAM)
CA (1) CA3039177A1 (OSRAM)
IL (1) IL258496A (OSRAM)
WO (1) WO2017062253A2 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790533B (zh) * 2016-08-15 2023-04-04 国立大学法人北海道大学 抗pd-l1抗体
WO2020123798A1 (en) * 2018-12-12 2020-06-18 President And Fellows Of Harvard College Bovine versions of fcmbl for the detection and treatment of bovine microbial infections
WO2022109313A1 (en) * 2020-11-20 2022-05-27 Zoetis Services Llc Bovine antibody variants
WO2025057225A1 (en) * 2023-09-14 2025-03-20 Invitrogen Bioservices India Private Limited Engineered antibodies and uses thereof
CN120209146A (zh) * 2025-03-31 2025-06-27 上海百英生物科技股份有限公司 一种包含非天然氨基酸修饰的Claudin 6抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP2244735A4 (en) * 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
US8647626B2 (en) * 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
EA201290241A1 (ru) * 2009-10-29 2013-02-28 Янссен Байотек Инк. Изменение гликозилирования антител
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
RU2013129203A (ru) * 2010-12-27 2015-02-10 Джапан Хелт Сайенсес Фаундейшн Моноклональное антитело, распознающее белок l2 папилломавируса человека (впч), и способ определения титра впч-нейтрализующего антитела, использующий такое антитело
EP2739650A4 (en) * 2011-08-01 2015-04-01 Avaxia Biologics Inc SPECIFIC BOVINE POLYCLONAL ANTIBODY OF HUMAN TNF
CN115850489A (zh) * 2016-08-15 2023-03-28 国立大学法人北海道大学 抗pd-1抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KNIGHT, KL. et al., 'Genetic engineering of bovine lg. Construction and characterization of hapten-binding bovine/murine chimeric IgE, IgA, IgG1, IgG2, and IgG3 molecules', The Journal of Immunology. 1988, vol. 140, no. 10, pages 3654-3659 *

Also Published As

Publication number Publication date
WO2017062253A3 (en) 2017-05-11
WO2017062253A2 (en) 2017-04-13
BR112018006953A2 (pt) 2018-10-23
CA3039177A1 (en) 2017-04-13
AU2023216791A1 (en) 2023-09-07
JP2018537117A (ja) 2018-12-20
US20220073602A1 (en) 2022-03-10
EP3359190A4 (en) 2020-05-06
IL258496A (en) 2018-05-31
JP7235287B2 (ja) 2023-03-08
US11891440B2 (en) 2024-02-06
JP2022185053A (ja) 2022-12-13
US20240067715A1 (en) 2024-02-29
AU2016335912A1 (en) 2018-05-24
EP3359190A2 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
US20240067715A1 (en) Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease
CN112513089A (zh) 抗cd73抗体、其抗原结合片段及应用
TW201837056A (zh) Ｂ７－ｈ３抗體、其抗原結合片段及其醫藥用途
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
US20190375839A1 (en) Tim-3 antibody, antigen binding fragment thereof, and medicinal uses thereof
CN113906053B (zh) 抗cea抗体及其应用
TW201900213A (zh) 免疫球蛋白ａ陽性細胞的調節
US20220396615A1 (en) Anti-human il6 monoclonal antibodies, preparation method therefor and use thereof
JP2025083342A (ja) ＴＧＦ－βＲＩＩ結合タンパク質
CN113260632A (zh) 包含IgA抗体构建体的组合物和方法
CN118647631A (zh) 用抗trem2抗体治疗纤维化
CA3183034A1 (en) Anti-pd1 antibodies and uses thereof
TW202112813A (zh) 對lif具有專一性的結合分子及其用途
CN114340668A (zh) 结合于cd38和cd3的异源二聚抗体
TW202346594A (zh) 經修飾之抗體及其用途
WO2022103871A1 (en) Therapeutic compositions for the treatment of covid-19
HK40094429A (en) Tgf-beta-rii binding proteins
WO2013172379A1 (ja) 新規抗体及びその用途
HK40045560A (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)